A Sequential, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of JNJ-80202135 Following a Single Intravenous Administration in Healthy Chinese Adult Participants
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Nipocalimab (Primary)
- Indications Autoimmune haemolytic anaemia; Chronic inflammatory demyelinating polyradiculoneuropathy; Haemolytic disease of newborn; Myasthenia gravis; Myositis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 30 Aug 2022 Planned primary completion date changed from 4 Jul 2022 to 12 Sep 2022.
- 30 Aug 2022 Status changed from recruiting to active, no longer recruiting.